No photo of Reem Karmali

View Scopus Profile

Reem Karmali

  • 629 Citations
20082024
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Training Experience

2009Residency, Rush University Medical Center
2012Fellowship, Rush University Medical Center

Education/Academic qualification

MS, Rush University

… → 2012

MD, University of Western Ontario

… → 2006

Fingerprint Dive into the research topics where Reem Karmali is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 19 Similar Profiles
Lymphoma Medicine & Life Sciences
Lymphoma, Large B-Cell, Diffuse Medicine & Life Sciences
Cell Transplantation Medicine & Life Sciences
Survival Medicine & Life Sciences
B-Cell Lymphoma Medicine & Life Sciences
Treatment Failure Medicine & Life Sciences
Follicular Lymphoma Medicine & Life Sciences
Mantle-Cell Lymphoma Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2013 2024

Prot #JCAR017-BCM-003: A Global Randomized Multicenter Phase 3 Trial to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects with High-Risk, Transplant-Eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TR

Karmali, R.

ICON Clinical Research, LLC, Celgene Corporation

10/21/19 → 10/21/22

Project: Research project

Prot #NDS-NHL-001: A Global, Non-Interventional, Retrospective, Multi-Center Study To Generate Real-World Evidence Of Treatment Outcomes In Subjects With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Karmali, R.

Quintiles, Inc., Celgene Corporation

9/18/19 → 9/18/24

Project: Research project

Prot #NEER-01: Network for Enigmatic Exceptional Responders to Cancer Treatment - The Cure is NEER

Karmali, R.

Takeda Pharmaceuticals U.S.A., Inc., Millennium Pharmaceuticals, Inc

6/12/19 → 6/12/22

Project: Research project

Prot #X34001/NU 18H02: A Phase 1 Study of R-CHOP Plus SYK Inhibitor TAK-659 for the Front-Line Treatment of High-Risk Diffuse Large B cell Lymphoma (DLBCL)

Karmali, R.

GMA Research Corporation, Millennium Pharmaceuticals, Inc

2/19/19 → 2/19/22

Project: Research project

Prot #GC-LTFU-001: Long-term Follow-up Protocol for Subjects Treated with Gene-Modified T Cells

Karmali, R.

ICON Clinical Research, LLC, Celgene Corporation

1/8/19 → 1/8/22

Project: Research project

Research Output 2008 2020

  • 629 Citations
  • 31 Article
  • 4 Review article
  • 1 Chapter

Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure

Ayers, E. C., Li, S., Medeiros, L. J., Bond, D. A., Maddocks, K. J., Torka, P., Mier Hicks, A., Curry, M., Wagner-Johnston, N. D., Karmali, R., Behdad, A., Fakhri, B., Kahl, B. S., Churnetski, M. C., Cohen, J. B., Reddy, N. M., Modi, D., Ramchandren, R., Howlett, C., Leslie, L. A. & 20 others, Cytryn, S., Diefenbach, C. S., Faramand, R., Chavez, J. C., Olszewski, A. J., Liu, Y., Barta, S. K., Mukhija, D., Hill, B. T., Ma, H., Amengual, J. E., Nathan, S., Assouline, S. E., Orellana-Noia, V. M., Portell, C. A., Chandar, A., David, K. A., Giri, A., Hess, B. T. & Landsburg, D. J., Jan 15 2020, In : Cancer. 126, 2, p. 293-303 11 p.

Research output: Contribution to journal › Article

B-Cell Lymphoma
Treatment Failure
Non-Hodgkin's Lymphoma
Vincristine
Doxorubicin

Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis

Shah, N. N., Ahn, K. W., Litovich, C., Sureda, A., Kharfan-Dabaja, M. A., Awan, F. T., Ganguly, S., Gergis, U., Inwards, D., Karmali, R., Lazaryan, A., Lekakis, L., Munshi, P., Nathan, S., Saad, A. A., Solh, M., Steinberg, A., Vij, R., Wood, W. A., Fenske, T. S. & 2 others, Smith, S. & Hamadani, M., Dec 1 2019, In : Blood cancer journal. 9, 12, 97.

Research output: Contribution to journal › Article

Open Access
Cell Transplantation
Homologous Transplantation
Non-Hodgkin's Lymphoma
Disease-Free Survival
Survival

Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin

Badar, T., Hamadani, M., Bachanova, V., Maddocks, K. J., Umyarova, E., Chavez, J. C., Epperla, N., Chhabra, S., Xavier, A. C., Karmali, R., Salhab, M., Reddy, N., Glenn, M. J., Hernandez-Ilizaliturri, F. J., Flowers, C. R., Evens, A. M., Zhou, Z., Lansigan, F., Barta, S. K., Cohen, J. B. & 2 others, Fenske, T. S. & Costa, L. J., Mar 21 2019, In : Leukemia and Lymphoma. 60, 4, p. 940-946 7 p.

Research output: Contribution to journal › Article

Lymphoma, Large B-Cell, Diffuse
Treatment Failure
Drug Therapy
B-Lymphocytes
Ifosfamide

Evaluation of the impact of cachexia on clinical outcomes in aggressive lymphoma

Burkart, M., Schieber, M., Basu, S., Shah, P., Venugopal, P., Borgia, J. A., Gordon, L. I. & Karmali, R., Jul 2019, In : British Journal of Haematology. 186, 1, p. 45-53 9 p.

Research output: Contribution to journal › Article

Cachexia
Lymphoma
Insulin-Like Growth Factor Binding Protein 6
Sarcopenia
Lymphotoxin-alpha

Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2

Godfrey, J. K., Nabhan, C., Karrison, T., Kline, J. P., Cohen, K. S., Bishop, M. R., Stadler, W. M., Karmali, R., Venugopal, P., Rapoport, A. P. & Smith, S. M., Jun 1 2019, In : Cancer. 125, 11, p. 1830-1836 7 p.

Research output: Contribution to journal › Article

B-Cell Lymphoma
Lymphoma
Maximum Tolerated Dose
Vincristine
Prednisone